Johnson & Johnson defends hemostatic powder patent at European appellate level as Baxter International challenge results in narrowed but upheld IP right
A Johnson & Johnson unit has successfully defended its patent for a hemostatic powder — a medical product used to control bleeding — before European patent appellate officials, who approved a narrower version of the patent despite objections from Baxter International. The decision means the J&J intellectual property right survives in modified form, with the scope of protection reduced rather than extinguished. The proceeding took place before the European Patent Office (EPO)'s Board of Appeal, which handles post-grant challenges to European patents. Baxter's opposition sought to invalidate the patent entirely; the outcome represents a partial win for each side — J&J retains protection, but over a narrower claim set. The specific modifications to claim scope have not been detailed in available reporting, but the survival of the patent in any form preserves J&J's commercial position in the haemostatic products market. This type of EPO opposition and appeal proceeding is a significant venue for life sciences and medtech patent disputes in Europe, running in parallel to — and often interacting with — national court proceedings in jurisdictions including the UK and Germany. The law firm Carpmaels & Ransford is identified in associated reporting as connected to the matter, though in what capacity the sources do not specify. The case illustrates the multi-jurisdictional nature of European patent enforcement: EPO decisions on claim scope bind all designated national markets simultaneously.
Why this matters
EPO opposition and appeal proceedings are a core area of IP disputes practice for London firms advising pharmaceutical and medtech clients, because EPO outcomes directly affect patent validity across all European Patent Convention member states including the UK. A narrowing of claim scope at the EPO level creates immediate downstream legal work — clients need advice on whether existing licence agreements, distribution contracts, or manufacturing arrangements remain within or outside the surviving patent claims. The emergence of the Unified Patent Court (UPC) as an additional European forum adds complexity, as UPC central division proceedings on validity can now run alongside EPO oppositions. The 'why now' is the ongoing expansion of the UPC's jurisdiction and the post-Brexit divergence of UK patent courts from EU frameworks.
On the Ground
On an IP disputes matter at the EPO appellate level, a trainee would be preparing chronology documents setting out the prosecution and opposition history of the patent, conducting disclosure review of technical documents submitted as prior art, and assisting with the preparation of witness statement bundles for any national court proceedings that follow the EPO decision.
Interview prep
Soundbite
A narrowed-but-upheld EPO patent is a trigger for licence and distribution contract reviews across every European market simultaneously.
Question you might get
“How does a successful EPO opposition that results in a narrowed patent claim affect a competitor's freedom to operate in European markets?”
Full answer
J&J has defended its hemostatic powder patent at the EPO Board of Appeal, obtaining approval of a narrower claim scope over Baxter's opposition — a common outcome that preserves commercial protection while reducing its breadth. For law firms, the significance lies in the downstream work: every licensing arrangement or freedom-to-operate analysis that was based on the original broader claims now needs revisiting. The wider picture is that EPO opposition proceedings are increasingly the venue of choice for challenging life sciences patents at scale, particularly post-Brexit when UK court proceedings no longer align with EU enforcement. This is likely to sustain IP disputes mandates for firms with both EPO prosecution and national court litigation capability.
Sources
My notes
saved